SEC Tracker
Get the app

Sangamo Therapeutics SGMOQ

Sangamo Therapeutics files amended operating reports

Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Major
  1. Filed amended monthly operating reports for July 2026 and August 2026
  2. Filed monthly operating report for September 2026
  3. Company is under Chapter 11 bankruptcy protection
  4. Stock delisted from Nasdaq and now trades on OTC

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Sangamo Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Monopar Therapeutics MNPR public float $156M, Jun 30, 2025
  2. Alpha Cognition ACOG public float $149M, Jun 30, 2025
  3. Aclaris Therapeutics ACRS public float $149M, Jun 30, 2025
  4. Forte Biosciences FBRX public float $157M, Jun 30, 2025
  5. Neurogene NGNE public float $146M, Jun 30, 2025